Allergan Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALLERGAN, and when can generic versions of ALLERGAN drugs launch?
ALLERGAN has seventy-three approved drugs.
There are nine US patents protecting ALLERGAN drugs.
There are one hundred and eighty-one patent family members on ALLERGAN drugs in fifty-five countries and one hundred and seventeen supplementary protection certificates in eighteen countries.
Summary for Allergan
International Patents: | 181 |
US Patents: | 9 |
Tradenames: | 70 |
Ingredients: | 54 |
NDAs: | 73 |
Patent Litigation for Allergan: | See patent lawsuits for Allergan |
PTAB Cases with Allergan as patent owner: | See PTAB cases with Allergan as patent owner |
Drugs and US Patents for Allergan
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan | TAZORAC | tazarotene | GEL;TOPICAL | 020600-002 | Jun 13, 1997 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
Allergan Herbert | EXSEL | selenium sulfide | LOTION/SHAMPOO;TOPICAL | 083892-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Allergan | GELNIQUE 3% | oxybutynin | GEL, METERED;TRANSDERMAL | 202513-001 | Dec 7, 2011 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Allergan | BYSTOLIC | nebivolol hydrochloride | TABLET;ORAL | 021742-004 | Dec 17, 2007 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Allergan | SAPHRIS | asenapine maleate | TABLET;SUBLINGUAL | 022117-003 | Mar 12, 2015 | AB | RX | Yes | No | 8,022,228*PED | ⤷ Sign Up | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Allergan
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Allergan | KADIAN | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 020616-003 | Jul 3, 1996 | 5,378,474 | ⤷ Sign Up |
Allergan | URSO 250 | ursodiol | TABLET;ORAL | 020675-001 | Dec 10, 1997 | 4,859,660 | ⤷ Sign Up |
Allergan | OCUFEN | flurbiprofen sodium | SOLUTION/DROPS;OPHTHALMIC | 019404-001 | Dec 31, 1986 | 3,793,457 | ⤷ Sign Up |
Allergan | TAZORAC | tazarotene | CREAM;TOPICAL | 021184-002 | Sep 29, 2000 | 5,089,509 | ⤷ Sign Up |
Allergan | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-002 | Oct 8, 2008 | 5,760,485 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ALLERGAN drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2007-10-16 |
➤ Subscribe | Sublingual Tablets | 5 mg and 10 mg | ➤ Subscribe | 2013-08-13 |
➤ Subscribe | Extended-release Capsules | 60 mg | ➤ Subscribe | 2009-03-02 |
➤ Subscribe | Transdermal System Extended-re | 3.9 mg/24 hrs | ➤ Subscribe | 2008-08-19 |
➤ Subscribe | Ophthalmic Solution | 0.30% | ➤ Subscribe | 2007-07-19 |
➤ Subscribe | Tablets | 2.5 mg, 5 mg, 10 mg, and 20 mg | ➤ Subscribe | 2011-12-19 |
➤ Subscribe | Sublingual Tablets | 2.5 mg | ➤ Subscribe | 2017-07-27 |
➤ Subscribe | Capsules | 4 mg and 8 mg | ➤ Subscribe | 2012-10-09 |
➤ Subscribe | Ophthalmic Solution | 0.05% | ➤ Subscribe | 2008-10-14 |
International Patents for Allergan Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Croatia | P20030034 | ⤷ Sign Up |
Malaysia | 140638 | ⤷ Sign Up |
Argentina | 086972 | ⤷ Sign Up |
Brazil | 112013032415 | ⤷ Sign Up |
France | 2812635 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Allergan Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1304992 | 92401 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE |
1304992 | C300617 | Netherlands | ⤷ Sign Up | PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322 |
1480644 | 2016C/069 | Belgium | ⤷ Sign Up | PRODUCT NAME: ZAVICEFTA (COMBINAISON DE CEFTAZIDIME ET AVIBACTAM); AUTHORISATION NUMBER AND DATE: EU/1/16/1109/001 20160628 |
1453521 | C 2015 029 | Romania | ⤷ Sign Up | PRODUCT NAME: LEVONORGESTREL SI ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: RO 7793/2015/001; DATE OF NATIONAL AUTHORISATION: 20150612; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): SK. 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150129 |
0392059 | 2002C/035 | Belgium | ⤷ Sign Up | PRODUCT NAME: MEMANTINE; REGISTRATION NO/DATE: EU/1/02/219/001 20020517 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.